Xencor, Inc. (XNCR)

NGM – Real Time Price. Currency in USD

12.44

-0.35 (-2.74%)

At close: May 12, 2026, 4:00 PM EDT

12.44

0.00 (0.00%)

After-hours: May 12, 2026, 4:50 PM EDT

06.05.2026

Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates

Xencor (XNCR) came out with a quarterly loss of $1.71 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to a loss of $0.66 per share a year ago.

06.05.2026

Xencor Reports First Quarter 2026 Financial Results

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2026. “Xencor continues to execute across our wholly owned clinical pipeline, with significant progress in both oncology and autoimmune disease. We look forward to presenting expansion cohort data from our Phase 1 study of XmAb819 for t.

05.05.2026

Xencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 Transcript

04.05.2026

Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported final results from the Phase 1 study of XmAb942, a novel, potential best-in-class, long-acting anti-TL1A antibody for the treatment of inflammatory bowel disease (IBD). The results are being presented today at Digestive Disease Week® (DDW), being held in Chicago. Tomorrow, the company will a.

11.03.2026

Xencor, Inc. (XNCR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

04.03.2026

Xencor Announces Change to Ultomiris® Royalty Revenue Forecast

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that Alexion Pharmaceuticals, Inc. (the “Licensee”) informed Xencor, Inc. (the “Company”) that it has taken the position that the Licensee does not owe any additional royalties for sales of Ultomiris® (ravulizumab-cwvz) in the United States and that the Licensee does not intend to make any.

26.02.2026

Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates

Xencor (XNCR) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $0.62 per share a year ago.

Videos

No Data

There is no data to display

Press releases

06.05.2026

Xencor Reports First Quarter 2026 Financial Results

04.03.2026

Xencor Announces Change to Ultomiris® Royalty Revenue Forecast

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that Alexion Pharmaceuticals, Inc. (the “Licensee”) informed Xencor, Inc. (the “Company”) that it has taken the position that the Licensee does not owe any additional royalties for sales of Ultomiris® (ravulizumab-cwvz) in the United States and that the Licensee does not intend to make any.

25.02.2026

Xencor Reports Fourth Quarter and Full Year 2025 Financial Results

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025. “Xencor's lead oncology drug candidate is XmAb819, a novel first-in-class T-cell engager that could offer a much-needed new therapeutic modality for patients with advanced clear cell renal cell carcinoma (ccRCC).

08.01.2026

Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced corporate priorities and 2026 pipeline advancement milestones for its clinical-stage portfolio of novel XmAb® drug candidates. “Xencor designs proteins that enable potential first-in-class and best-in-class medicines for patients, and we are building on momentum from 2025, when we presented.

Xencor, Inc. (XNCR)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Xencor, Inc. (XNCR)

Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates

Xencor Reports First Quarter 2026 Financial Results

Xencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 Transcript

Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW

Xencor, Inc. (XNCR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Xencor Announces Change to Ultomiris® Royalty Revenue Forecast

Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates

Videos

No Data

Press releases

Xencor Reports First Quarter 2026 Financial Results

Xencor Announces Change to Ultomiris® Royalty Revenue Forecast

Xencor Reports Fourth Quarter and Full Year 2025 Financial Results

Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones

Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates

Xencor Reports First Quarter 2026 Financial Results

Xencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 Transcript

Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW

Xencor, Inc. (XNCR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Xencor Announces Change to Ultomiris® Royalty Revenue Forecast

Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates

Videos

No Data

Press releases

Xencor Reports First Quarter 2026 Financial Results

Xencor Announces Change to Ultomiris® Royalty Revenue Forecast

Xencor Reports Fourth Quarter and Full Year 2025 Financial Results

Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones

Search stocks

Xencor, Inc. (XNCR)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Xencor, Inc. (XNCR)

Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates

Xencor Reports First Quarter 2026 Financial Results

Xencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 Transcript

Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW

Xencor, Inc. (XNCR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Xencor Announces Change to Ultomiris® Royalty Revenue Forecast

Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates

Videos

No Data

Press releases

Xencor Reports First Quarter 2026 Financial Results

Xencor Announces Change to Ultomiris® Royalty Revenue Forecast

Xencor Reports Fourth Quarter and Full Year 2025 Financial Results

Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones

Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates

Xencor Reports First Quarter 2026 Financial Results

Xencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 Transcript

Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW

Xencor, Inc. (XNCR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Xencor Announces Change to Ultomiris® Royalty Revenue Forecast

Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates

Videos

No Data

Press releases

Xencor Reports First Quarter 2026 Financial Results

Xencor Announces Change to Ultomiris® Royalty Revenue Forecast

Xencor Reports Fourth Quarter and Full Year 2025 Financial Results

Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones